Last reviewed · How we verify
Uabaina (ouabain)
Uabaina, a marketed drug by an unspecified company, operates by inhibiting STAT3, a critical protein in cell signaling pathways, but its primary indication and revenue figures are not specified. A key strength of Uabaina is its patent protection, which is set to expire in 2028, providing a significant period of market exclusivity. The primary risk lies in the competitive landscape, where off-patent drugs such as cisplatin, digitoxin, and digoxin, which target the same pathway, are widely available and have established market presence.
At a glance
| Generic name | ouabain |
|---|---|
| Drug class | ouabain |
| Target | Signal transducer and activator of transcription 3, Potassium voltage-gated channel subfamily H member 2, Sodium/potassium-transporting ATPase subunit alpha-1 |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Preop Digifab in CABG to Reduce Ouabain Levels and Prevent AKI (PHASE4)
- Genetics in the Progression of Nephropathies
- Antihypertensive Effect of Different Doses of Rostafuroxin in Comparison With Losartan (PHASE2)
- Renal Ageing-sarcopenia Network
- Efficacy of Rostafuroxin in the Treatment of Essential Hypertension (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Uabaina CI brief — competitive landscape report
- Uabaina updates RSS · CI watch RSS
- portfolio CI